Reason for request
Re-assessment of the Actual Benefit and Improvement in Actual Benefit in accordance with article R-163-21 of the Social Security Code.
Clinical Benefit
| Substantial |
The actual benefit of RISPERDAL and RISPERDALORO in the treatment of schizophrenia remains substantial. |
Clinical Added Value
| moderate |
Like all other antipsychotics (including typical an tipsychotics), RISPERDAL and RISPERDALORO provide a moderate improvement in actual benefit (IAB III) in the treatment of schizophrenia. |
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
Shz6SVeKa2mrDCbr
